Pooled analysis of single-arm studies of Budesonide/Glycopyrronium/Formoterol (BGF) in routine care setting

Trial Identifier: D5980R00084
Sponsor: AstraZeneca
Collaborator:
IQVIA
Start Date: April 2025
Primary Completion Date: September 2026
Study Completion Date: September 2026
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada Mississauga, Canada
Germany Hamburg, Germany
Greece Athens, Greece
Italy Milan, Italy
Japan Tokyo, Japan
Romania Bucharest, Romania
United Kingdom London, United Kingdom